BN Business News
Add your company to Business Communicator →

Business · 18/12/2023Updated: 10/17/2026 · 1 min read

Pharmacyclics LLC Withdraws FDA Approval for IMBRUVICA Indications for MCL and MZL

Summary

Pharmacyclics LLC has voluntarily withdrawn FDA approval of indications for mantle cell lymphoma and marginal zone lymphoma for IMBRUVICA (ibrutinib) capsules and tablets, citing a request to the FDA.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →